Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205675
Type of Stem Cell Treatment:
Allogeneic - Unrelated
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
Primary objective:
The objective of the study is to evaluate the outcome of patients with MDS who underwent allogeneic HSCT and received GvHD prophylaxis with cyclophosphamide post-transplantation compared to those who received Antithymocyte Globulin (ATG).
The primary endpoint of the study is GvHD-free/relapse free survival (GRFS).
The primary endpoint of the study is GvHD-free/relapse free survival (GRFS).
Key inclusion criteria:
o Diagnosis of MDS or MDS transformed to AML before first allogeneic HSCT.
o Adults (≥18 years) at time of transplantation.
o First allogeneic HSCT between 2012-2019.
o Stem cell source: bone marrow or peripheral blood from an unrelated donor.
o Post-cyclophosphamide (post-CY) as GvHD prophylaxis or Antithymocyte Globulin (ATG) as conditioning or GvHD prophylaxis treatment.
o Adults (≥18 years) at time of transplantation.
o First allogeneic HSCT between 2012-2019.
o Stem cell source: bone marrow or peripheral blood from an unrelated donor.
o Post-cyclophosphamide (post-CY) as GvHD prophylaxis or Antithymocyte Globulin (ATG) as conditioning or GvHD prophylaxis treatment.
Country:
Principal investigator:
Yves Chalandon, Marie Robin
EBMT Study coordinator:
Laurien Baaij
Study coordinator email:
cmwpebmt@lumc.nl